An autoantibody, developed by a patient with severe and recurrent arterial thrombosis, was characterized to be directed against the anion-binding exosite of thrombin, and inhibited all thrombin interactions requiring this secondary binding site without interfering with the catalytic site. The effect of the antibody was studied on thrombin interactions with platelots and endothelial cells from human umbilical veins (HUVEC). The autoantibody specifically and concentration-dependently inhibited a-thrombin-induced platelet activation and prostacyclin (PGI,) synthesis from HUVEC. It had no effect when ythrombin or the thrombin receptor activation peptide SFLLR were the inducers. The effect of the antibody on protein C activation has been studied. The E PREVIOUSLY described an autoantibody specific for human thrombin in a patient presenting with unexplained severe recurrent arterial thrombosis.' This antibody inhibits the interaction of thrombin with fibrinogen, fibrin, heparin cofactor 11, and thrombomodulin, and has no effect on the interaction of thrombin with synthetic substrates. The study of various recombinant thrombin mutants allowed the demonstration that the antibody recognized a narrow region in the anion-binding exosite. ' Antithrombin antibodies are not frequent, and are usually observed with bleeding disease^.'^^.^ The occurrence of such autoantibodies is usually associated with autoimmune disorders6 or a crossed immunization with bovine thrombin: but never with a thrombotic disease. No other immune and coagulation disorder was detected in the present case. Because abnormalities of platelets and/or the vessel wall are typically involved in arterial thrombosis,' the present study was designed to evaluate the antibody effect on thrombin interactions with platelets and endothelial cells, which are both mediated by a thrombin receptor recently identified.' The purified autoantibody inhibited a-thrombin-induced platelet aggregation and release, endothelial cell prostacyclin production, and thrombin-thrombomodulin protein C activation in a concentration-dependent manner.
An autoantibody, developed by a patient with severe and recurrent arterial thrombosis, was characterized to be directed against the anion-binding exosite of thrombin, and inhibited all thrombin interactions requiring this secondary binding site without interfering with the catalytic site. The effect of the antibody was studied on thrombin interactions with platelots and endothelial cells from human umbilical veins (HUVEC). The autoantibody specifically and concentration-dependently inhibited a-thrombin-induced platelet activation and prostacyclin (PGI,) synthesis from HUVEC. It had no effect when ythrombin or the thrombin receptor activation peptide SFLLR were the inducers. The effect of the antibody on protein C activation has been studied. The E PREVIOUSLY described an autoantibody specific for human thrombin in a patient presenting with unexplained severe recurrent arterial thrombosis.' This antibody inhibits the interaction of thrombin with fibrinogen, fibrin, heparin cofactor 11, and thrombomodulin, and has no effect on the interaction of thrombin with synthetic substrates. The study of various recombinant thrombin mutants allowed the demonstration that the antibody recognized a narrow region in the anion-binding exosite. ' Antithrombin antibodies are not frequent, and are usually observed with bleeding disease^.'^^.^ The occurrence of such autoantibodies is usually associated with autoimmune disorders6 or a crossed immunization with bovine thrombin: but never with a thrombotic disease. No other immune and coagulation disorder was detected in the present case. Because abnormalities of platelets and/or the vessel wall are typically involved in arterial thrombosis,' the present study was designed to evaluate the antibody effect on thrombin interactions with platelets and endothelial cells, which are both mediated by a thrombin receptor recently identified. ' The purified autoantibody inhibited a-thrombin-induced platelet aggregation and release, endothelial cell prostacyclin production, and thrombin-thrombomodulin protein C activation in a concentration-dependent manner.
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MATERIALS AND METHODS
Case report. The patient R.D. has been described previously.'
Briefly, she presented with a history of recurrent arterial thrombosis without clearness of atherosclerosis, vasculitis of the arterial wall, or cardiologic disorders. In 1988, an extensive laboratory investigation showed a prolonged thrombin clotting time (TCT) performed with human thrombin with otherwise normal biochemical and immunologic tests. Further studies allowed the description of the presence of an immune inhibitor of thrombin characterized as antithrombin polyclonal IgGs specific for human thrombin, and still present at the time we prepared this report. Purijcation of the antibody. Specific IgGs were obtained by a three-step procedure from the patient (IgG D), and from a normal subject (control IgGs). Plasma was diluted with 0.01 mom phosphate buffered saline (PBS), pH 7.8 (1:l vol/vol), and precipitated by the addition of increasing doses of ammonium sulfate. The fractions, antibody blocked the thrombin-thrombomodulin activation of protein C. The inhibition of the activation was maximal with a low concentration of thrombomodulin. The fact that the autoantibody inhibited concentration-dependent athrombin-induced platelet and endothelial cell functions emphasizes the crucial role of the anion-binding exosite of thrombin to activate its receptor. In regard to the pathology, the antibody inhibited two vascular processes ismplicated in thrombin-antithrombotic functions, PGlz secretion, and protein C activation, which could be implicated in this arterial thrombotic disease. (ml) den) and 50 pL of solution of IgG were incubated for 90 seconds at 37°C. After addition of human thrombin (1 NIH-U/mL) (Stago) in 20 mmoVL Tris HCI, 0.15 m o a NaCl, 0.5% polyethylene glycol 6,000, pH 7.8, buffer, the clotting time was recorded. The antithrombin activity was determined by the amount of thrombin neutralized, expressed as 1 U corresponding to the neutralization of 1 U-NIH thrombin. A reference curve was established by performing various TCTs in the presence of increasing concentrations of thrombin.
Thrombin receptor-derived peptide. The peptide SFLLRs.9 was synthesized and purified by D r Troalen (Institut Gustave Roussy, Villejuif, France). The peptide FSLLR was used as a control.'o Platelet preparation and functions. Blood was collected from donors who had not taken any drug for 7 days, and anticoagulated with ACD-C (12.4 mmoVL sodium citrate, 13 mmoVL citric acid, 11 mmoVL glucose; 9:l vol/vol). Platelet-rich plasma (PRP) was obtained by 15 minutes of centrifugation of blood at 100 X g, and incubated for 20 to 30 minutes with [14C] 5-hydroxytryptamine ([I4C] 5-HT) (18.5 kBq/lO mL) (Amersham, Les Ulis, France) at room temperature. Platelets were isolated by a 15-minute centrifugation at 1,100 X g and 20°C on a metrizamide gradient (Nycomed Pharma AS, Oslo, Norway). The metrizamide gradient platelets (MGP) thus obtained were adjusted to 3 X 108/mL in a buffer, pH 7.4 (10 mmoV L Hepes, 140 mmoVL NaCI, 3 mmoVL KCI, 5 mmoVL NaHC03, 10 mmoVL glucose, 0.5 mmoVL MgCI?).
Platelet aggregation was recorded on an aggregometer (Chrono Log, Coultronics, Margency, France).
The suspension was prewarmed to 37°C for 30 seconds before the addition of 0. Endothelial cell isolation and culture. Human umbilical veins (HUVEC) were washed with PBS (GIBCO, Pontoise, France) at 37T, and endothelial cells obtained by incubation with of 0.025% collagenase (GIBCO) at 37°C in PBS buffer for 12 minutes. Cell viability was tested by 0.01% Blue trypan coloration (Sigma). Cells were grown to confluency on gelatin-coated flasks, T-25 Primaria (Falcon Dickinson, Lincoln Park, NJ) with culture medium M199/ RPMI 1640 (GIBCO) supplemented with 20% fetal calf serum o;vhlttaker, Fontenay-sous-Bois, France), 250 IU/mL penicillin, 100 pg/mL streptomycin, and 1 mmoVL glutamine in a 5% C02/95% air atmosphere at 37°C. The cells were passaged with 0.025% trypsin-EDTA, and grown in six-well culture plates with the same experimental conditions. Cells were used at confluency at the second or third passage. For personal use only. on August 30, 2017. by guest www.bloodjournal.org From Prostacyclin liberation induced by various agonists. HUVEC were stimulated by various agonists during 5 minutes at room temperature. The reaction was stopped by the addition of 0.5 mL of a mixture. of 50 mmol/L acetic acid, 0.1N HCl in methanol. Prostacyclin (PGI,) was measured in the culture supernatant by the assay of the stable analog of prostacyclin, the 6-keto prostaglandin F1, (PGFl,), with a competitive radioimmunologic assay with ['H] 6-keto PGFl, on a scintillation proximity assay system (Amersham).
Human protein C activation. Protein C activation was determined in presence of IgG D and control IgGs in Tris HCl20 mmoY L, NaCl 0.1 morn, pH 7.4, buffer, containing 0.1% bovine serum albumin (wtlvol) (Sigma). IgGs (1 to 6 prnom) were incubated with 3.3 nmol/L human thrombin during 5 minutes at 22°C. Rabbit thrombomcdulin (American Diagnostica Inc, Greenwich, CT) was added (15 to 45 nmol/L). After 5 minutes at 37°C. the reaction was started by the addition of protein C (0.75 pmovL, Stago) at 37°C. After 2,4, and 8 minutes of activation, aliquots of 25 pL were taken and added to 4 pmol/L antithrombin purified as described'' and 0.14 IU/mL heparin in a 96-well microplate, according to Zhang and Castellino." Activated protein C generation was quantified at 22°C using 0.8 mmol/L substrate S 2366 (Chromogenix, Molndal, Sweden) at 405 nm with a kinetic program on a microplate reader MR SO00 (Dynatech Laboratories, Guyancourt, France). The initial velocity (Vi) corresponded to the slope of the linear relation between the variation of absorbance per minute and the time of incubation.
RESULTS
Purijication of the autoantibody. The IgGs were first purified by chromatography on Protein G-Sepharose representing a fourfold enrichment of the antithrombin activity. However, because control IgGs isolated with the same procedure induced unspecific effects on any agonist-induced platelet aggregation, a further purification was required. This was performed on a thrombin-Sepharose column as previously described.' The enrichment of the immunopurified fraction was poor, and was not improved by blocking the thrombinactive site by the specific inhibitor tosyl-lysine-chloromethylketone (TLCK). Therefore, we used another strategy, taking advantage of the elution of the patient's IgGs displaying antithrombin activity in only two of the 25 eluted fractions from a Q-Sepharose column (Fig 1) . The patient's and normal IgGs used in this study were purified by the threestep procedure described in the Methods. Ammonium sulfate precipitation, Q-Sepharose, and Protein G-Sepharose columns led to a final 22-fold enrichment. The active fraction of IgGs was included in a band corresponding to migration of control IgGs, as shown on SDS-PAGE (Fig 2) . The specific activity (1 10 U/mg) of such an active fraction was higher than that obtained after immunopurification on active siteblocked thrombin-Sepharose column.
Effect of the autoantibody on plateletfunctions. Purified antithrombin IgGs had no aggregating effect by themselves, nor had any unspecific effect on ADP-or collagen-induced aggregation (data not shown). However, when human thrombin was the inducer, an inhibitory effect was observed (Fig  3) . Identical inhibitory effect was measured whether the IgGs were preincubated for 10 minutes at 37°C with thrombin or were added just before thrombin. Normal IgGs were used as control, and never had any effect on any platelet function. Forty microliters of the patient's IgGs inhibited 0.75 nmoY L and 1 nmom a-thrombin by 47% and 50% for aggregation and 70% and 60% for secretion, respectively. By contrast, it had no effect when y-thrombin was the agonist. The inhibitory effect on a-thrombin was increased with increasing IgGs concentrations (Fig 4) . Using 120 p g / d of IgGs (0.8 pmol/L) resulted in an almost complete inhibition of aggregation, and secretion of 5-hydroxytryptamine. By contrast, whatever the concentration of control IgGs used, no inhibition was ever observed on y-thrombin-induced aggregation and release (Fig 5) .
The peptide SFLLR described as the receptor amino acid sequence responsible for activation, was also used as an aggregation agonist to further characterize the effect of the patient's IgGs on the interaction of thrombin with its platelet receptor. extents as in the presence of l nmol/L a-thrombin (Fig 6) . No inhibitory effect of patient's IgGs (80 pg/mL) was observed, not even with higher IgG concentrations (120 or 160 (data not shown). The peptide FSLLR, used as a control, induced no aggregation (data not shown).
Effect of the autoantibody on endothelial cells. Basal PGIz production by HUVEC, measured as the 6-keto PGFl,, was increased between five to eight times in the presence of In the presence of 2 mg/mL (1 3 pmol/L) of the patient's IgGs, only the a-thrombin-induced PG12 was completely inhibited. When y-thrombin (or histamine) was the inducer, the PG12 production was unaffected by the presence of the autoantibody (Fig 7) .
Effect of the autoantibody on thrombin-thrombomodulin uctivation sf protein C. The effect of purified IgGs on protein C activation was first determined in the presence of thrombomodulin 15 nmol/L (Fig 8) . The patient's IgGs inhibited protein C activation in a concentration-dependent manner. Almost complete inhibition was observed with 0.9 mg/mL of the patient's IgGs (6 pmol/L), corresponding approximately to the circulating concentration previously evaluated as 5% of the total IgGs.
The effect of different concentrations of thrombomodulin on the inhibition of protein C activation by the patient's IgGs (6 pmol/L) is shown in Fig 9. The patient's IgGs inhibited protein C activation up to 45 nmoVL of thrombomodulin, a concentration above which the antibody no longer had an inhibitory effect. These results show that the antibodydependent inhibition of protein C activation depends on the number of available thrombomodulin molecules.
DISCUSSION
The autoantibody studied in the present report was found in a patient suffering from severe arterial thrombosis, and was characterized to be directed specifically against human thrombin.' The effects of the autoantibody on thrombinplasma proteins interactions indicated that it was directed against the anion-binding exosite,' and a further study using thrombin mutants' allowed the demonstration that the domain of thrombin recognized by the autoantibody clearly overlaps the anion-binding exosite.
Thrombin is a serine protease, generated at the end of a series of enzymatic reactions caused by a vascular lesion, known to play a crucial role in hemostasis. It transforms fibrinogen in fibrin, aggregates platelets, and favors its own production by activating several coagulation factors. At the same time, it is able to downregulate its own production by binding to thrombomodulin on the endothelium surface to activate the coagulation inhibitor protein C, and to activate endothelial cell PG12 production. Thrombin thus interacts both with cells and circulating proteins, all of which are interactions that require the integrity of the thrombin molecule, ie, a recognition site or anion-binding exosite, and a catalytic domain.
Cellular responses to thrombin are consecutive to the cleavage of the thrombin receptor.' Indeed, the thrombin receptor is now well described with its seven transmembrane domains, and a sequence in the N-terminal part homologous to the C-terminal end of h i r~d i n . '~ Thrombin recognition of its receptor occurs through the anion-binding exosite, which bears the specificity, whereas the information for activation is given by the cleavage of the receptor by the catalytic domain of thrombin, demasking a new N-terminal extremity of the receptor (SFLLR . . .), which becomes the agonist.
In the case presented here, the autoantibody inhibited specifically a-thrombin-induced platelet aggregation, but had no effect when the synthetic peptide SFLLR or y-thrombin, the autoproteolytically cleaved thrombin that has lost the anion-binding site,14 were the agonists. Such a reduction in a-thrombin-induced platelet aggregation was previously shown in conditions in which the anion-binding site was blocked by the presence of the C-terminal sequence of hirudin . IgG Control (mg/ml) PG12 production by in vitro-cultured endothelial cells stimulated by a-thrombin was strongly and concentration-dependently reduced, whereas the patient's IgGs had no effect when y-thrombin was the inducer. It is of note that in our conditions, and in the absence of IgGs, a significant amount of PGIz was produced by 50 nmom y-thrombin, a production which has been reported only in response to much higher y-thrombin concentration^.^' Thus, the antibody rendered thrombin less effective for the activation of its receptor, both on platelets and on endothelial cells, and a similar thrombidantibody ratio was necessary tinent for studying the role of the anion exosite of thrombin in the activation of its receptor. Moreover, the fact that the inhibition was concentration-dependent implies that the graded blocking of the anion-binding exosite leads to the graded response of the receptor to thrombin, as recently dem~nstrated.'~"~ In vitro, the autoantibody delayed all procoagulant actions of thrombin, such as fibrin formation and platelet aggregation, but also the PG12 production from endothelial cells. Although pGIz is the most powerful antiaggregant, the inhibition of its production cannot by itself explain thrombotic as severe as those observed in our patient. Thrombin interaction with other molecules of the endothelial cell surface, such as thrombomodulin, may also be involved in the pathology.
Indeed, the autoantibody dose-dependently prevented the endothelial cell surface decreases on various stimulation, such as tumor necrosis factor:' interleukin-l/?," and endoIn such conditions, the antibody could compete with thrombomodulin for protein C activation, and consequently render the vascular antithrombotic response to procoagulant stimuli less effective. In addition, differences in thrombomodulin expression among various endothelia in the bodyM may also explain the localization of the patient's thrombosis to large arteries.
In conclusion, this antithrombin autoantibody, first detected with a prolonged TCT in the presence of human thrombin, inhibited PGIl secretion and protein C activation subsequent to thrombin formation on the vascular surface, two major processes, the inhibition of which represents a risk factor for the patient to develop thrombosis.
